New Comment Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease www.thelancet.com/journals/lan...

New Research Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study www.thelancet.com/journals/lan...

New Research Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial www.thelancet.com/journals/lan...

New Research Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 www.thelancet.com/journals/lan...

New Review: Kyasanur Forest disease: an emerging arboviral threat www.thelancet.com/journals/lan...

New Comment G20 2025: advancing equity and affordability in future tuberculosis vaccines for adolescents and adults www.thelancet.com/journals/lan...

The November issue is now live! www.thelancet.com/journals/lan... Post-partum haemorrhage www.thelancet.com/journals/lan... Impact of breastfeeding on the global burden of NCDs in mothers and children www.thelancet.com/journals/lan... Vaccine ecosystem in Africa www.thelancet.com/journals/lan...

📅 Marco De Ambrogi will be attending ASTMH 2025, #TropMed25, November 9-13, 2025 in Toronto, Ontario, Canada on behalf of The Lancet Infectious Diseases! 📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

Derivation and external validation of community-acquired #pneumonia subphenotypes in Southeast Asia: a secondary analysis of prospective cohort studies These subphenotypes may represent unique targets for future #CAP interventional trials www.thelancet.com/journals/ecl... #MedSky

New Research Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial www.thelancet.com/journals/lan...

New Research Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study www.thelancet.com/journals/lan...

New comment: Tuberculosis and undernutrition: improving estimates to reinforce the policy imperative www.thelancet.com/journals/lan...

Community-acquired pneumonia is the leading infectious cause of morbidity and mortality globally. Yet, there are several challenges associated with diagnosis, treatment, and long-term management of Community-acquired pneumonia. Find out more in a new Seminar: tinyurl.com/hd2fwz7n

New Personal View Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development www.thelancet.com/journals/lan...

New podcast @steventong.bsky.social Buzzsprout - www.buzzsprout.com/1740310/epis... Apple - podcasts.apple.com/gb/podcast/i... Spotify - open.spotify.com/episode/588l...

Read our November issue! Featuring testing olorofim to treat fungal infections, introduction of nirsevimab for RSV in Chile, and new oxazolidinones for tuberculosis therapy. www.thelancet.com/issue/S1473-...

New comment Elimination of measles and rubella in Pacific island countries and areas www.thelancet.com/journals/lan...

📅 @phoebedownes.bsky.social will be attending ID Week, #IDWeek (19-22 October) in Atlanta, GA on behalf of The Lancet Infectious Diseases! 📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

Our October issue is now online: www.thelancet.com/journals/lan... Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #Trypanosoma #Chagas #Streptococcus #AMR #gonorrhoea #cytomegalovirus #cholera #mpox #TB #IDSky #ClinMicro #OA

New Research Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial www.thelancet.com/journals/lan...

New Review Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) www.thelancet.com/journals/lan...

New Review The Emerging Resistance Index: tracking early resistance to new antibiotics www.thelancet.com/journals/lan...

New Research Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study www.thelancet.com/journals/lan...

New Research Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study www.thelancet.com/journals/lan...

New Research Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial www.thelancet.com/journals/lan...

New Personal View: Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings www.thelancet.com/journals/lan...

New Research: Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study www.thelancet.com/journals/lan...

Our October issue is now live! lnkd.in/eezpGTwq Featuring: 👉 An Editorial on the burden of NCDs among people of South Asian heritage www.thelancet.com/journals/lan... 👉 A Comment urging global health policy makers to recognise obesity as a disease www.thelancet.com/journals/lan... #HLM4

Read our October issue! Featuring a trial testing moxidectin for lymphatic filariasis, bedaquiline resistance and tuberculosis outcomes, and a recombinant influenza vaccine for children. www.thelancet.com/issue/S1473-...

New Research: Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial www.thelancet.com/journals/lan...

🗓️ Saleha Hassan will be attending the Global AMR Innovators Conference, #GAMRIC2025 (1-3 October) in London on behalf of The Lancet Infectious Diseases! 📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

New comment #Diagnostics at the frontline: using the Public Accounts Committee report to catalyse the UK’s antimicrobial resistance diagnostics strategy www.thelancet.com/journals/lan... #IDSky #ClinMicro #AMR #OpenAccess #OA

New Personal View: Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali www.thelancet.com/journals/lan...

New Research: Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomised, controlled, dose-ranging, phase 2 trial www.thelancet.com/journals/lan...

The role of AI in infectious diseases is emerging—offering new opportunities for infection prevention, outbreak detection & control. But challenges like data fragmentation & trust remain. Explore a new @thelancetinfdis.bsky.social Series ⤵️ bit.ly/4nbkHrh

New Research: Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial www.thelancet.com/journals/lan...

🆕📢“As vertical HIV programmes collapse... primary health care, with its syndemic approach and infrastructure for chronic disease management, is well positioned to absorb HIV services while ensuring sustainability” Read the Viewpoint ➡️ www.thelancet.com/journals/lan...

New Editorial: More data needed on the FDA's decision to suspend Ixchiq www.thelancet.com/journals/lan...

New Research Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China: phase 3, multicentre, randomised, double-blind, controlled, non-inferiority trial www.thelancet.com/journals/lan...

New Review: Autoantibodies in long COVID: a systematic review www.thelancet.com/journals/lan...

New Research: A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial www.thelancet.com/journals/lan...

New Research: Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories www.thelancet.com/journals/lan...

🗓️ Claire Lenahan will be attending the 6th ESCMID Conference on #Vaccines 2025 (10th-13th September) in Lisbon on behalf of The Lancet Infectious Diseases! 📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

📰The Lancet Respiratory Medicine’s September issue is out now Read content on obstructive sleep apnoea, #tuberculosis, cardiogenic shock, #pneumonia, and much more Check out the full issue here: bit.ly/3P2PVls

New comment: Preventing vertical HIV transmission in India: the final push www.thelancet.com/journals/lan...

Congratulations to our Chair, A/Prof Meru Sheel, on her profile in The Lancet Infectious Diseases. The article highlights her incredible work in infectious diseases, immunisation & acute emergency responses 💉🦠 @thelancetinfdis.bsky.social @merusheel.bsky.social Read here: shorturl.at/4D8wO

New Research: Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial www.thelancet.com/journals/lan...

New Review: Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia www.thelancet.com/journals/lan...

Just published in @thelancetinfdis.bsky.social: A PREMISE pilot study shows how real-time immune surveillance in kids can predict virus rebounds and prepare us for the next pandemic. A key read for #InfectiousDisease professionals. #PedsID #epidemiology

New Personal View: A transformation in cholera surveillance www.thelancet.com/journals/lan...